ArticleBMC bioinformatics2026
Robust graph structure learning to improve multi-omics cancer subtype classification.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundClassifying cancer patients into consistent subtypes at the multi-omics level remains a significant challenge in advancing precision medicine. Nevertheless, a key problem in integrating multi-omics data lies in concurrently addressing intra-omics and inter-omics information, along with sample networks.
resultsIn this study, we introduce the Feature and Graph Structure-Learning Integrated Graph Convolutional Network (FaGGCN), which combines feature learning and graph structure learning for multi-omics cancer subtyping. The model employs convolutional autoencoders to learn information-rich latent features, and patient survival information is further leveraged to select key features that are significantly associated with survival outcomes. The graph autoencoder fuses the key features with inter-omics similarity fusion matrices, enabling the model to learn a comprehensive sample network. Finally, the graph convolutional network integrates the key features while incorporating the sample network to precisely classify patients. Additionally, survival analysis, sensitivity analysis, and differential gene expression analysis highlight the interpretability of the FaGGCN model, as well as its ability to identify biomarkers suitable for clinical research.
conclusionsExperimental results show that our model achieves competitive performance across eight cancer datasets spanning four omics modalities, with generally improved classification performance and exploratory survival prediction results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.